**Author details**

Milad Rasouli1 \*, Nadia Fallah<sup>2</sup> and Kostya (Ken) Ostrikov3

1 Department of Physics, Institute for Plasma Research, Kharazmi University, Tehran, Iran

2 Department of Cellular and Molecular Biology, Faculty of Biological Science, Kharazmi University, Tehran, Iran

3 School of Chemistry and Physics and Institute for Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia

\*Address all correspondence to: miladrasouli@outlook.com

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**195**

ijc.28323

nnano.2007.387

*Nano Technology and Gas Plasma as Novel Therapeutic Strategies for Ovarian Cancer…*

Farokhzad OC. Nanotechnology and aptamers: applications in drug delivery. Trends in biotechnology. 2008 Aug 1;26(8):442-9. doi.org/10.1016/j.

[9] Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology:

the impact of passive and active targeting in the era of modern cancer biology. Advanced drug delivery reviews. 2014 Feb 1;66:2-5. doi. org/10.1016/j.addr.2013.11.009

[10] Uma Prabhakar, Hiroshi Maeda, Rakesh K. Jain, Eva M. Sevick-Muraca, William Zamboni, Omid C. Farokhzad, et al., Cancer Res April 15 2013 (73) (8) 2412-2417; DOI: 10.1158/0008-5472.

[11] Tibbitt MW, Dahlman JE, Langer R. Emerging frontiers in drug delivery. Journal of the American Chemical Society. 2016 Jan 27;138(3):704-17. DOI:

[12] Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities.

Jan;17(1):20. doi:10.1038/nrc.2016.108

[13] Metelmann HR, Von Woedtke T, Weltmann KD, editors. Comprehensive clinical plasma medicine: cold physical plasma for medical application.

[14] Dai X, Bazaka K, Thompson E, Ostrikov K. Cold Atmospheric Plasma: A Promising Controller of Cancer Cell States, Cancers. MDPI AG; 2020 Nov 13;12(11):3360. doi.org/10.3390/

[15] Zhou R, Zhou R, Wang P, Xian Y, Mai-Prochnow A, Lu X, Cullen PJ, Ostrikov KK, Bazaka K. Plasma-activated water: generation, origin of reactive species and

Nature Reviews Cancer. 2017

tibtech.2008.04.006.

CAN-12-4561

10.1021/jacs.5b09974

Springer; 2018 May 4.

cancers12113360

*DOI: http://dx.doi.org/10.5772/intechopen.96387*

[1] Kurman, Robert J. MD; Shih, Ie-Ming MD, PhD The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory, The American Journal of Surgical Pathology: March 2010 - Volume 34 - Issue 3 - p 433-443 doi: 10.1097/

PAS.0b013e3181cf3d79

**References**

[2] Wiegand KC, Shah SP,

Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W. ARID1A mutations in endometriosis-associated ovarian carcinomas. New England Journal of Medicine. 2010 Oct 14;363(16):1532-43. doi.org/10.1056/NEJMoa1008433

[3] Galluzzi, L., Senovilla, L., Vitale, I. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869-1883 (2012). doi.org/10.1038/onc.2011.384

[4] Ishaq, M., Evans, M., and Ostrikov, K., (2014), Effect of atmospheric gas plasmas on cancer cell signaling. Int. J. Cancer, 134: 1517-1528. doi.org/10.1002/

[5] Peer, D., Karp, J., Hong, S. et al. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech 2, 751-760 (2007). doi.org/10.1038/

[6] Dai X, Bazaka K, Richard DJ, Thompson ER, Ostrikov KK. The emerging role of gas plasma in

oncotherapy. Trends in biotechnology. 2018 Nov 1;36(11):1183-98. doi. org/10.1016/j.tibtech.2018.06.010.

[7] Dai X, Yu L, Zhao X, Ostrikov KK. Nanomaterials for oncotherapies targeting the hallmarks of cancer. Nanotechnology. 2020 Sep;31(39):392001. doi. org/10.1088/1361-6528/ab99f1.

[8] Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, *Nano Technology and Gas Plasma as Novel Therapeutic Strategies for Ovarian Cancer… DOI: http://dx.doi.org/10.5772/intechopen.96387*
